WILMINGTON, Del. — AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases, furthering the AstraZeneca cell therapy ambition. The proposed acquisition will enrich AstraZeneca’s growing pipeline of cell therapies with...
Latest News
AstraZeneca’s Alexion has exercised its option to acquire all remaining equity in Caelum Biosciences for CAEL-101, a potentially first-in-class fibril-reactive monoclonal antibody (mAb) for the treatment of light chain (AL) amyloidosis. AL amyloidosis is a rare disease in which misfolded amyloid proteins build up in organs throughout the body, including...
WILMINGTON, Del. — Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed...
Cambridge, England – AstraZeneca on Monday released high-level results from the Phase III LAURA study, demonstrating clinical benefit for Tagrisso (osimertinib) as a maintenance treatment for patients with unresectable, stage III, EGFR-mutated non-small cell lung cancer. The pharma did not reveal specific data in its announcement but said that Tagrisso...
BOSTON, Mass. — Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 clinical trial evaluating STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. Initial results demonstrate...
AUSTIN, Texas — Natera, Inc., a global leader in cell-free DNA testing, presented new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, at the American Society of Clinical Oncology’s 2024 Gastrointestinal Cancers Symposium (ASCO GI), that took place January 18 – 20, 2024 in San Francisco,...
STOCKHOLM — Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), today announced data presentations highlighting additional analyses from the Phase 3 NefIgArd study with Nefecon in adults with primary IgA nephropathy (IgAN), as well as pre-clinical data on the treatment of Alport syndrome with setanaxib, a novel NOX inhibitor,...
THOUSAND OAKS, Calif. — Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced its recent submission of an Investigational New Drug (IND) application to the U.S. Food...
SOUTH SAN FRANCISCO, Calif. – Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company has joined the Rare Disease Company Coalition. The coalition represents an alliance of...
SOUTH SAN FRANCISCO, Calif.- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced a combined long-term overall survival (OS) analysis from three clinical...